FOLH1 and neoplasm: This work presents the development and preclinical evaluation of a novel PSMA-T4 ligand (Glu-CO-Lys-L-Trp-4-Amc-HYNIC), which showed excellent radiolabeling characteristics, high selectivity towards PSMA receptors in vitro and favorable tumor accumulation in LNCaP tumor-bearing mice.